Article
Biotechnology & Applied Microbiology
Xiaoyu Liu, Wanqi Yang, Chao Zhang, Heng Wu, Ruize Wang, Qiang Ding, Yan Hu, Yongli Xiong, Shaobai Zhang, Lin Wang
Summary: This study demonstrated that the co-administration of enterovirus 71 (EV71) vaccine with measles-mumps-rubella (MMR) vaccine and live-attenuated Japanese encephalitis vaccine (LA-JEV) showed no interference with antibody response and had good safety profiles. This strategy is suitable for healthy infants in increasing vaccination uptake and reducing clinic visits.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Immunology
Mya Myat Ngwe Tun, Aung Kyaw Kyaw, Khine Mya Nwe, Shingo Inoue, Kyaw Zin Thant, Kouichi Morita
Summary: A study conducted among monastic school children in Mandalay, Myanmar showed that 87% of students still had neutralizing antibodies against JEV six months after receiving the SA-14-14-2 live-attenuated vaccine. Antibody titers increased with age, with statistically significant differences noted across age groups.
Article
Immunology
Zhimei Zhao, Yuyi Liao, Yuan Li, Guorun Jiang, Zhuhang Huang, Huijuan Yang, Zhiqiang Ou, Qiongzhou Yin, Junhu Chen, Yan Deng, Ruiju Jiang, Yanchun Che, Qihan Li, Huizhen Zheng, Jikai Zhang
Summary: Simultaneous administration of EV71 vaccine with MR vaccine in infants demonstrates robust and noninferior antibody responses compared to separate administration, with similar reactogenicity and safety profiles.
Article
Immunology
Michael Desjardins, Xhoi Mitre, Amy C. Sherman, Stephen R. Walsh, Matthew P. Cheng, Sanjat Kanjilal, Vincent T. Ho, Lindsey R. Baden, Nicolas C. Issa
Summary: This study assessed the safety of MMR vaccine when administered within 2 years of hematopoietic cell transplant (HCT), showing that the vaccine appears to be well tolerated in select HCT recipients between 300 and 729 days after transplant. An uncomplicated case of vaccine-associated rubella illness was identified, but the patient fully recovered, with no other vaccine-associated illnesses identified in the cohort after a median follow-up of 676 days. Further assessment of potential risks and benefits of MMR vaccination within 2 years of HCT is deemed important.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Public, Environmental & Occupational Health
L. Preethi, M. S. Alina, Lakshmi Chandran, S. Asvin, M. Jagadeesan, T. M. Vijayakumar, V Chitra, Ashok Kumar Pandey, Mahendra M. Reddy, Brij Ranjan Misra, Rajni Kant, Prudhvi Lal Bhukya, Gururaj Rao Deshpande, Priya Abraham, Gajanan Sapkal, Kamran Zaman
Summary: This study evaluates the persistence of the immune response to the live attenuated SA-14-14-2 JE vaccine after two doses. The results show a decreasing trend of the immune response with increasing duration after vaccination, highlighting the importance of booster doses for children in endemic areas.
JOURNAL OF TRAVEL MEDICINE
(2023)
Review
Public, Environmental & Occupational Health
Mateusz Hasso-Agopsowicz, Natasha Crowcroft, Robin Biellik, Christopher J. Gregory, Marion Menozzi-Arnaud, Jean-Pierre Amorij, Philippe-Alexandre Gilbert, Kristen Earle, Collrane Frivold, Courtney Jarrahian, Mercy Mvundura, Jessica J. Mistilis, David N. Durrheim, Birgitte Giersing
Summary: Measles and rubella microarray patches (MR-MAPs) are crucial for eradicating measles and rubella, but it is unlikely for them to be prequalified by the WHO and ready for use before 2033 due to various limitations. This article discusses the progress, challenges, and opportunities associated with MR-MAPs manufacturing, regulatory approval, demand creation, and licensure timelines. It also highlights ongoing efforts by multiple partners to incentivize investment and expedite the development of MR-MAPs.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Multidisciplinary Sciences
Lorena Sanchez-Felipe, Thomas Vercruysse, Sapna Sharma, Ji Ma, Viktor Lemmens, Dominique Van Looveren, Mahadesh Prasad Arkalagud Javarappa, Robbert Boudewijns, Bert Malengier-Devlies, Laurens Liesenborghs, Suzanne J. F. Kaptein, Carolien De Keyzer, Lindsey Bervoets, Sarah Debaveye, Madina Rasulova, Laura Seldeslachts, Li-Hsin Li, Sander Jansen, Michael Bright Yakass, Babs E. Verstrepen, Kinga P. Boszormenyi, Gwendoline Kiemenyi-Kayere, Nikki van Driel, Osbourne Quaye, Xin Zhang, Sebastiaan ter Horst, Niraj Mishra, Ward Deboutte, Jelle Matthijnssens, Lotte Coelmont, Corinne Vandermeulen, Elisabeth Heylen, Valentijn Vergote, Dominique Schols, Zhongde Wang, Willy Bogers, Thijs Kuiken, Ernst Verschoor, Christopher Cawthorne, Koen Van Laere, Ghislain Opdenakker, Greetje Vande Velde, Birgit Weynand, Dirk E. Teuwen, Patrick Matthys, Johan Neyts, Hendrik Jan Thibaut, Kai Dallmeier
Summary: The candidate vaccine YF-S0, utilizing the YF17D vaccine as a vector to express noncleavable prefusion form of the SARS-CoV-2 spike antigen, showed excellent safety, immunogenicity, and efficacy in animal models. It induced high levels of neutralizing antibodies, provided protective immunity against SARS-CoV-2, and prevented infection in hamsters and macaques. A single dose was able to confer protection from lung disease in most vaccinated hamsters within 10 days, highlighting the potential of YF-S0 as a potent SARS-CoV-2 vaccine candidate.
Article
Immunology
Santosh Kumar Verma, Dheeraj Shah, Aaradhana Singh, Praveen Kumar Singh, Shukla Das, Piyush Gupta
Summary: This study aimed to assess the immunogenicity of measles-rubella (MR) vaccine in Indian children below one year of age. The results showed that the MR vaccine administered under India's Universal Immunization Programme resulted in a high level of seroprotection against rubella and measles. The seroprotection rates for rubella were 97.5% and 100%, and for measles were 88.7% and 100% after the first and second doses, respectively.
INDIAN JOURNAL OF MEDICAL RESEARCH
(2023)
Article
Immunology
Mona Marin, Amy Parker Fiebelkorn, Daoling Bi, Laura A. Coleman, Janell Routh, Aaron T. Curns, Huong Q. McLean
Summary: The research found that the reported adverse events in young adults receiving a third measles-mumps-rubella (MMR) vaccine (MMR3) in a non-outbreak setting were mild and transient, indicating that MMR3 is safe and tolerable in this population.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Oncology
Zumama Khalid, Simona Coco, Nadir Ullah, Alessandra Pulliero, Katia Cortese, Serena Varesano, Andrea Orsi, Alberto Izzotti
Summary: This study evaluates the therapeutic effect of the MMR vaccine on cancer, specifically Glioblastoma (GBM). The results show significant reduction in viability of GBM cells after MMR treatment, suggesting the potential use of MMR vaccine in GBM therapy.
Article
Public, Environmental & Occupational Health
Yong Chan Kim, Heejin Nam, Jun Yong Choi, Eui-Cheol Shin, Young Hwa Choi
Summary: Young healthcare workers with low measles antibody positivity rates after two doses of measles vaccine showed significantly higher seropositivity and increased neutralizing antibody titers following a third dose of measles vaccine. Additionally, the third dose enhanced measles virus-specific T-cell effector function in this population.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2023)
Article
Biotechnology & Applied Microbiology
Dapeng Sun, Dan Yu, Zhenhua Du, Ningning Jia, Xiaodong Liu, Jianwen Sun, Qing Xu, Zhuoqun Sun, Chunfang Luan, Jingjing Lv, Ping Xiong, Li Zhang, Xueyan Sha, Yongjun Gao, Dianmin Kang
Summary: Co-administration of live attenuated varicella vaccine and inactivated hepatitis A vaccine in children aged 12-15 months showed non-inferior immunogenicity and safety profiles compared to separate administration of the vaccines.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Immunology
Marco Fonzo, Annamaria Nicolli, Stefano Maso, Lorenzo Carrer, Andrea Trevisan, Chiara Bertoncello
Summary: This study investigated the relationship between overweight/obesity and antibody persistence after vaccination against measles, mumps, rubella (MMR), and hepatitis B virus (HBV). The results showed that there was no significant association between lack of serologic protection and BMI for both HBV vaccine and each component of the MMR vaccine.
Article
Medicine, General & Internal
Arabella S. Stuart, Robert H. Shaw, Xinxue Liu, Melanie Greenland, Parvinder K. Aley, Nick J. Andrews, J. C. Cameron, Sue Charlton, Elizabeth A. Clutterbuck, Andrea M. Collins, Tom Darton, Tanya Dinesh, Christopher J. A. Duncan, Anna England, Saul N. Faust, Daniela M. Ferreira, Adam Finn, Anna L. Goodman, Christopher A. Green, Bassam Hallis, Paul T. Heath, Helen Hill, Bryn M. Horsington, Teresa Lambe, Rajeka Lazarus, Vincenzo Libri, Patrick J. Lillie, Yama F. Mujadidi, Ruth Payne, Emma L. Plested, Samuel Provstgaard-Morys, Maheshi N. Ramasamy, Mary Ramsay, Robert C. Read, Hannah Robinson, Gavin R. Screaton, Nisha Singh, David P. J. Turner, Paul J. Turner, Iason Vichos, Rachel White, Jonathan S. Nguyen-Van-Tam, Matthew D. Snape
Summary: The study investigated the mixed use of different COVID-19 vaccines within the same schedule, showing that in certain conditions, heterologous vaccination can achieve similar immunogenicity to homologous vaccination, facilitating rapid global vaccine deployment.
Letter
Immunology
Cristina Costales, Malaya K. Sahoo, ChunHong Huang, Carolina V. Guimaraes, Donald Born, Lauren Kushner, Hayley A. Gans, Thuy A. Doan, Benjamin A. Pinsky
Summary: This article reports a fatal case of vaccine-associated measles encephalitis in an immunocompromised child in California, USA. The infection was confirmed by whole-genome RNA sequencing of measles virus from brain tissue. Biased matrix-gene hypermutation consistent with persistent measles virus central nervous system infection was observed.
EMERGING INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Xinhua Chen, Wei Wang, Xinghui Chen, Qianhui Wu, Ruijia Sun, Shijia Ge, Nan Zheng, Wanying Lu, Juan Yang, Lance Rodewald, Hongjie Yu
Summary: The study shows that a homologous third dose of COVID-19 vaccines can provide higher neutralizing antibody levels and better protection against the Delta variant compared to the primary series. Irrespective of vaccine technology, all types of vaccines included in the study are predicted to effectively prevent symptomatic and severe cases of COVID-19 caused by the Delta variant.
Article
Immunology
Meredith G. Dixon, Milagritos D. Tapia, Kathleen Wannemuehler, Richard Luce, Mark Papania, Samba Sow, Myron M. Levine, Marcela F. Pasetti
Summary: Measles is endemic and fatal among infants in Africa. Maternal immune status affects infant measles antibody titre at birth. Older mothers are more likely to have had natural measles infection, resulting in higher antibody titre than vaccine-induced immunity. This study investigated the relationship between maternal age and measles susceptibility in mother-infant pairs in Mali. The results showed that infants born to younger mothers were more susceptible to measles at birth and three months, and by six months almost all infants were susceptible. It is important to improve measles immunization coverage, especially among nonimmune reproductive-aged women and older children, to protect susceptible infants from infection and death.
Article
Gastroenterology & Hepatology
Cielo Yaneth Rios-Hincapie, Rocio Murad-Rivera, Rania A. Tohme, Alba Maria Ropero, Bertha Gomez, Diana Librado Cardona, Brigitte Neffer Forest Duque, Diego Cuellar, Ivan Cardenas, Elisabeth Krow-Lucal, Kathleen Wannemuehler, Fernando de la Hoz Restrepo, Sandra Marcela Sanchez-Molano, Carlos Eugenio Delgado, Juan Carlos Rivillas-Garcia, Annemarie Wasley
Summary: A two-phase method was used to verify the elimination of HBV mother-to-child transmission in Colombia, identifying high-risk municipalities and conducting a household serosurvey of children. The results suggest that Colombia has likely achieved the goal of eliminating HBV transmission.
JOURNAL OF VIRAL HEPATITIS
(2022)
Article
Immunology
Porcia Manandhar, Kathleen Wannemuehler, M. Carolina Danovaro-Holliday, Laura Nic Lochlainn, Stephanie Shendale
Summary: This study assessed the use of the second-year-of-life (2YL) platform for catch-up vaccination in Pakistan, the Philippines, and South Africa. The results showed that these countries have increased vaccine coverage through catch-up vaccination in 2YL, but there are still missed opportunities for vaccination. Immunization programs need to change policies, practices, and monitor catch-up vaccination to maximize the potential.
Article
Immunology
Chao Ma, Chang Huang, Wenrui Wang, Yudan Song, Xiaofeng Jiang, Xiaoling Tian, Boxi Liu, Fuli Chi, Shengli Lang, Dongyan Liu, Weiwei Sun, Lin Tang, Dan Wu, Yifan Song, Junhong Li, Lance Rodewald, Zundong Yin, Zhijie An
Summary: Phase 3 clinical trials and real-world effectiveness studies have demonstrated that China's inactivated COVID-19 vaccines are highly effective in preventing serious illness. During an outbreak in Inner Mongolia in November 2021, the effectiveness of these vaccines against the delta variant was evaluated through a retrospective cohort study of close contacts. The results showed that full vaccination reduced symptomatic infection by 62%, pneumonia by 64%, and severe COVID-19 by 90%, while homologous booster doses further increased the effectiveness.
Article
Medicine, General & Internal
Hong Yang, Qi Qi, Yong Zhang, Ning Wen, Lei Cao, Yu Liu, Chunxiang Fan, Dongmei Yan, Xiaoping Zhu, Lixin Hao, Shuangli Zhu, Qianli Ma, Jiajie Liu, Chao Ma, Lei Nan, Yong Chen, Xiaozhen Ma, Na Chen, Kun Deng, Ge Shao, Xianxiang Ding, Zhijie An, Lance E. Rodewald, Xiaolei Li, Dongyan Wang, Hui Zhu, Huaqing Wang, Zijian Feng, Wenbo Xu, Jiushun Zhou, Zundong Yin
Summary: This study investigated the response to a VDPV2 outbreak in Sichuan Province, China. Sabin-strain IPV campaigns were used for supplementary immunization activities and various measures such as specimen testing and environmental surveillance were conducted. The outbreak was successfully controlled.
Article
Infectious Diseases
Carla Vizzotti, Jennifer B. Harris, Analia Aquino, Carolina Rancano, Cristian Biscayart, Romina Bonaventura, Andrea Pontoriero, Elsa Baumeister, Maria Cecilia Freire, Mirta Magarinos, Blanca Duarte, Gavin Grant, Susan Reef, Janeen Laven, Kathleen A. Wannemuehler, Alba Maria Ropero Alvarez, J. Erin Staples
Summary: The study assessed the potential immune interference that could result from co-administration of measles, mumps, rubella (MMR) and yellow fever (YF) vaccines in childhood vaccination schedules. The results showed that co-administration of MMR and YF vaccines is effective, although antibody levels for two antigens were lower.
BMC INFECTIOUS DISEASES
(2023)
Article
Immunology
Lin Tang, Fu-Zhen Wang, Lance E. Rodewald, Xuan-Yi Wang, Si-Yu Liu, Qian-Qian Liu, Xiao-Qi Wang, Dan Wu, Ming-Shuang Li, Qian Zhang, Yi-Ming Shao, Li-Fang Huang, Yu-Dan Song, Yong Huang, Xiang Zeng, Li-Jun Liu, Hong Yang, Ao-Di Huang, Li-Ming Bao, Hui Zheng, Chao Ma, Xiao-Ya Lv, Lei Song, Zhao Ma, Shu-Guang Wang, Hao Ma, Wei-Jie Guan, Zhi-Yin Wu, Nan-Shan Zhong, Zun-Dong Yin
Summary: Inactivated COVID-19 vaccines in China provide modest protection against infection but good and excellent protection against pneumonia and severe/critical COVID-19, respectively. Booster doses are necessary for stronger protection.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Medicine, General & Internal
Fuzhen Wang, Baoying Huang, Yao Deng, Shaobai Zhang, Xiaoqiang Liu, Lei Wang, Qianqian Liu, Li Zhao, Lin Tang, Wenling Wang, Xiaoqi Wang, Fei Ye, Weijun Hu, Haitao Yang, Siquan Wang, Jiao Ren, Xiaoyu Liu, Cangning Wang, Xuhua Guan, Ruize Wang, Yan Zheng, Xianfeng Zhang, Hui Zheng, Dan Wu, Zhijie An, Wenbo Xu, Lawrence E. Rodewald, George F. Gao, Zundong Yin, Wenjie Tan
Summary: This study found that using injectable or inhaled aerosolized adenovirus-vectored COVID-19 vaccines as heterologous boosters after an inactivated COVID-19 vaccine primary series significantly increased neutralizing antibody levels against the ancestral SARS-CoV-2 virus. Inhaled aerosolized vaccine showed superior efficacy compared to the injectable vaccine.
Article
Immunology
Fu-Zhen Wang, Chun-Huan Zhang, Lin Tang, Lance E. Rodewald, Wen Wang, Si-Yu Liu, Wen-Ji Wang, Dan Wu, Qian-Qian Liu, Xiao-Qi Wang, Li-Fang Huang, Ao-Di Huang, Li-Ming Bao, Zhou-Bin Zhang, Zun-Dong Yin
Summary: A prospective, observational cohort study in China estimated the short-term effectiveness of an inhaled adenovirus type 5-vectored COVID-19 vaccine as a second booster dose against Omicron BA.5 infection. The vaccine showed a relative effectiveness of 61% in 18-59 year-olds and 38% in ≥60 year-olds, sustained for 12 weeks. The study's findings were based on real-world data during China's SARS-CoV-2 BA.5 variant epidemic wave.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Editorial Material
Infectious Diseases
Lance E. Rodewald
Summary: China conducted a large-scale vaccination campaign during the COVID-19 zero infection period, reaching over 90% of the population with highly effective vaccines. The campaign strengthened and expanded the national immunization program, achieving high coverage and vaccinating millions of adults. The momentum from this campaign should be invested into a well-resourced national immunization program capable of reaching everyone in the country.
INFECTIOUS DISEASES OF POVERTY
(2023)
Article
Medicine, General & Internal
Karol M. Pencina, Thomas G. Travison, Andrew S. Artz, A. Michael Lincoff, Steven E. Nissen, Panagiotis Flevaris, Anna Chan, Xue Li, Scott A. Diegel, Kathleen Wannemuehler, Shalender Bhasin
Summary: This study assessed the efficacy of testosterone replacement therapy (TRT) in correcting anemia in men with hypogonadism and found that TRT was more effective than placebo in correcting anemia. Additionally, TRT was also found to reduce the risk of developing anemia in men without anemia.
Article
Public, Environmental & Occupational Health
Pinpin Zhu, Dan Wu, Yan Wang, Xiaoxue Liu, Lance E. Rodewald, Yixing Li, Hui Zheng, Lei Cao, Yifan Song, Li Song, Xiaodong Zhao, Jianyi Yao, Fuzhen Wang, Mingshuang Li, Qian Zhang, Tingting Yan, Zundong Yin
Summary: This study shows that the effectiveness of co-purified DTaP vaccine against pertussis-related illnesses increases with the number of doses administered. Previous research indicated VE rates of 42% for one dose, 88% for two doses, and 95% for three doses. However, this new study found that VE rates range from 24%-26% after one dose to 86%-87% after four doses.
Article
Public, Environmental & Occupational Health
Ning Yao, Yang Liu, Jia-Wei Xu, Qing Wang, Zun-Dong Yin, Ning Wen, Hong Yang, Lance E. Rodewald, Zhi-Yong Zhang
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2022)
Article
Public, Environmental & Occupational Health
Dan Wu, Yanyang Zhang, Lin Tang, Fuzhen Wang, Ying Ye, Chao Ma, Hui Zheng, Wenzhou Yu, Lei Cao, Yifan Song, Abuduwaili Reyimu, Xiaoxiao Zhang, Haifeng Wang, Yifei Nie, Mingxia Lu, Muge Qi, Jun Li, Ruolin Wang, Kaichao Yang, Changshuang Wang, Lawrence Everett Rodewald, Geroge Fu Gao, Zhijie An, Zundong Yin
Summary: In an outbreak from a hospital setting, completion of primary vaccination with inactivated COVID-19 vaccines reduces the risk of symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant. Partial vaccination is ineffective, and completion of two doses of the primary vaccination is necessary for protection from Delta.